FeesSafety
Pluang+

InspireMD to report Q3 2026 financial results on Nov 12 with a live webcast and call.

Company Fundamentals
29 Oct 2026, 15:00 WIB
GlobeNewsWire
View Source
Neutral
InspireMD to report Q3 2026 financial results on Nov 12 with a live webcast and call.

InspireMD, developer of the CGuard Prime carotid stent system, will announce its third quarter 2026 financial results on November 12, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and recent developments. Interested parties can register online to participate and access the live audio webcast or archived recording on InspireMD's investor website. This update is important for investors tracking the company's progress in stroke prevention technology and upcoming FDA approvals.

InspireMD's upcoming third quarter 2026 financial results provide context for health-sector market activity on Pluang as of Oct 29, 2026 18:11 WIB. Among 150 health-sector US stocks priced on Pluang, 95 advanced while 47 declined. Novartis AG (NVS) traded at USD 160.96 with a 3.13% gain and a typical hold time of 84 days, contrasting with Sana Biotechnology Inc (SANA) at USD 2.71, up 3.04% but with a much shorter hold time of 25 days and a high 96% sell order activity. Inovio Pharmaceuticals Inc (INO) showed a price of USD 0.96, rising 3.38% with a 43-day hold time and a majority 65% sell order activity.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App